سرطان قناة فالوب المتقدم لدى الإناث: ماذا نفعل عندما لا يحقق العلاج الكيميائي المساعد الأولي الخفض المثالي للورم

References

• ASCO states that although primary cytoreductive surgery is preferred for patients with a high likelihood of achieving optimal debulking, women with high perioperative risk or a low likelihood of achieving optimal cytoreduction should receive neoadjuvant chemotherapy followed by possible interval surgery.
• To date, bevacizumab has been FDA approved for the following uses in epithelial ovarian cancer: in combination with carboplatin plus paclitaxel, followed by bevacizumab single agent for stage III or IV disease after initial surgical resection; in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent epithelial ovarian cancer after no more than two prior chemotherapy regimens; and in combination with carboplatin plus paclitaxel or carboplatin plus gemcitabine, followed by bevacizumab single agent, for platinum-sensitive recurrent epithelial ovarian cancer.
• All three drugs are approved for maintenance treatment of recurrence of epithelial ovarian cancer in patients with at least a partial response to platinum-based therapy.

DOI: 10.1200/JOP.18.00662